Side-effects
In pre-clinical animal studies of darunavir (Prezista), no particular safety concerns emerged. In the POWER studies, side-effects were mild to moderate, and were similar across all doses of darunavir. The commonest side-effects were diarrhoea, nausea and headache, but these were less common in the darunavir arms than in patients taking the comparator protease inhibitor[1][2]. Around 7% of patients also experienced skin rash, which was serious in a few cases.
latest aidsmap news
- Large HIV vaccine study will not go ahead
- Swiss court rules all people with HIV can be criminally liable for transmission, even if untested
- Genital shedding of HIV in women with undetectable viral load: less of it, but still happening
- Microbicides could prevent more infections in men than in women
- Knowledge of STIs poor in rural Tanzania - associated with risky sex and infection with HIV
- HIV treatment effective for infants in resource-limited settings
- Need for vigilance: two cases of abacavir allergy despite pre-treatment screening all-clear
- One third of people with HIV have experienced sexual difficulties in the past month
- Differing causes of lung infections in HIV-positive patients: implications for diagnosis and treatment
- Roche to halt HIV drug research